Skip to main content

Table 3 Targeted therapy protocols selected according to CTC: PBMC percentage gene overexpression ratios, and associated RECIST 1.1 responses

From: Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

Pt

EGFR %

VEGFR %

MDR1%

TYMS %

DHFR %

ERCC1%

GST %

Protocol of targeted therapy

Response in association with intraarterial chemotherapy

1R

45

70

80

0

0

0

18

BEV

PR

2R

45

70

80

0

0

0

10

BEV

PR

3R

50

65

65

0

0

0

10

BEV

PR

4R

50

20

55

0

0

0

10

CET

PR

5R

65

50

70

0

0

0

5

CET

PR

6R

50

80

70

0

0

0

10

BEV

PR

7R

50

20

80

10

0

25

20

CET

PR

8R

50

20

60

0

0

0

10

CET

PR

9R

50

30

65

10

0

0

10

CET

PR

10R

70

60

70

0

0

0

0

CET

PR

11R

60

55

65

5

0

0

10

CET

PR

12R

60

55

65

5

0

0

15

CET

PR

13R

40

70

80

5

10

0

10

BEV

PR

14R

50

70

70

0

0

0

10

BEV

PR

15R

50

20

65

0

0

0

15

CET

PR

16R

65

70

80

0

0

0

18

BEV

PR

17R

55

70

80

0

0

0

10

BEV

PR

18R

60

85

70

0

0

0

10

BEV

SD

19R

60

55

60

0

0

0

10

CET

SD

20R

70

45

58

0

0

0

12

CET

SD

21R

10

65

65

0

0

0

20

BEV

SD

22R

50

80

70

0

0

0

10

BEV

SD

23R

60

70

70

0

0

0

10

BEV

SD

24R

80

35

60

0

25

0

0

CET

SD

25R

60

70

70

0

0

0

0

BEV

SD

26R

40

80

70

5

0

15

15

BEV

SD

27R

40

60

60

0

0

0

10

BEV

SD

28 L

50

70

70

10

0

0

10

BEV

SD

29 L

40

50

60

0

10

0

10

BEV

SD

30 L

60

85

70

0

0

0

10

BEV

SD

31*L

65

80

83

0

0

0

10

BEV

SD

32 L

50

80

60

0

0

0

8

BEV

SD

33 L

60

90

70

0

0

0

10

BEV

SD

34 L

60

30

70

0

0

0

10

CET

SD

35*L

45

55

70

0

0

0

10

BEV

SD

36*L

50

80

70

0

0

0

10

BEV

PD

  1. CTC Circulating tumor cells, PMBCs Peripheral mononuclear blood cells, Pt Patient, R Patient with unresectable refractory recurrent rectal cancer, L Patient with unresectable refractory colo-rectal cancer liver metastases, EGFR Epidermal growth factor receptor, VEGFR Vascular endothelial growth factor receptor, MDR1 Multidrug resistance gene (ABCB1 gene), TYMS Thymidylate synthase gene, DHFR Dihydrofolate reductase, ERCC1 DNA excision repair protein, GST Glutathione S-transferases, BEV Bevacizumab (dosage administered = 5 mg/kg), CET Cetuximab (dosage administered = 250 mg/m2), PR Partial response, SD Stable disease, PD Progressive disease
  2. *KRAS (Kirsten rat sarcoma virus gene) mutated in codon 12, exon 2